The South San Francisco biotech plans to begin its first human trial of a liver cell-reprogramming therapy next year ...

NewLimit Raises $435M to advance longevity medicine trials, expand ageing research programmes and accelerate clinical growth.

NewLimit Series C raises $435M led by Founders Fund as Armstrong-backed startup moves epigenetic therapies toward human ...

AACR Trailblazer Grant recipients are tackling fundamental questions in cancer biology—from metastasis and immune evasion to ...

Mesenchymal drift may help explain how cells lose stable identity and acquire pro-fibrotic, inflammatory mesenchymal traits ...

Notably, the clinical trials MAGMA and JCOG1703 further demonstrated that some treatment regimens for newly diagnosed GBMs ...

Now worth $3.1 billion, NewLimit plans to test its RNA therapy in alcohol-related liver-disease patients next year ...

Longevity influencers promise to extend our lives with a mix of evidence and shady science. I’m willing to give it a try ...

Cancer cells evolve under constant pressure from oncogene activation, hypoxia, nutrient limitation, immune surveillance, and therapeutic exposure. These ...

At ASMS, Bruker Corporation (Nasdaq: BRKR) announced the launch of the unique timsMRMS system, bringing the power of trapped ion mobility separation to ultra-high-resolution magnetic resonance mass ...

Fueled by multi-billion-dollar valuations and a deeper understanding of aging biology, the field is rapidly moving past the hype and into the clinic.

Goldman Sachs 30th Annual European Financials Conference 2026 June 3, 2026 2:45 AM EDTCompany ParticipantsGeorges Elhedery - ...